Abacavir + dolutegravir + lamivudine for the treatment of HIV.

about

Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients.Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.

P2860

Q54267037-9BCBE330-B15B-490E-9A1B-44E4509D52D8 Q55280381-C2998CEA-053C-4900-AB7B-E34030B69FE8

P2860

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

Item

http://www.wikidata.org/entity/Q38951349

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

@en

type

Item

label

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

@en

prefLabel

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

@en

P1476

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

@en

P2093

Franco Maggiolo

http://www.w3.org/2001/XMLSchema#string

Laura Comi

http://www.w3.org/2001/XMLSchema#string

P2860

Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Abacavir and cardiovascular disease: A critical look at the data.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.

Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Single-Tablet Regimens in HIV Therapy

P304

2097-2106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1232387

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27616133

http://www.w3.org/2001/XMLSchema#string

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

about

P2860

P2860

Abacavir + dolutegravir + lamivudine for the treatment of HIV.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698